Last reviewed · How we verify
H001 Capsule 200mg-bid — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
H001 Capsule 200mg-bid (H001 Capsule 200mg-bid) — Livzon Pharmaceutical Group Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| H001 Capsule 200mg-bid TARGET | H001 Capsule 200mg-bid | Livzon Pharmaceutical Group Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- H001 Capsule 200mg-bid CI watch — RSS
- H001 Capsule 200mg-bid CI watch — Atom
- H001 Capsule 200mg-bid CI watch — JSON
- H001 Capsule 200mg-bid alone — RSS
Cite this brief
Drug Landscape (2026). H001 Capsule 200mg-bid — Competitive Intelligence Brief. https://druglandscape.com/ci/h001-capsule-200mg-bid. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab